YSB’s B2B Pharma Platform: Sexier Than the SOEs, But Stodgier Than B2Cs
The drug distributor for pharmacies and community-level medical institutions has filed for a Hong Kong listing, boasting strong revenue growth but also massive losses Key Takeaways: YSB has filed for…
RELATED ARTICLES
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK -
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
-
Hengrui Pharma accelerates bid for global brand status
600276.SHG
-
Airdoc Tech enjoys healing properties of medical AI rally
2251.HK
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
